Upcoming Events.
BIONNALE 2023
Marc Voigt, CEO of Immutep will participate in the upcoming event
Past Events.
J.P. Morgan 41st Annual Healthcare Conference
Marc Voigt, CEO and Deanne Miller, COO will be attending and hosting meetings at the 41st Annual J.P. Morgan Healthcare Conference taking place January 9-12, 2023 at the Westin St. Francis in San Francisco, CA.
The JMP Securities Hematology and Oncology Summit
Marc Voigt, CEO of Immutep will participate in the event virtually and will deliver a corporate presentation.
Speaking time of Marc Voigt: 11:20 AM ET on Wednesday, 7 Deccember 2022
For questions, please email DBroderick@LJFevents.com
Annual General Meeting 2022
Immutep Annual General Meeting 2022 will be taking place at Offices of Piper Alderman, Governor Macquarie Tower, 1 Farrer Place, Sydney, NSW on Wednesday, 23 November 2022, 11.00 am (AEDT)
13th Annual Jefferies London Healthcare Conference
Marc Voigt, CEO of Immutep will participate in the upcoming in-person conference
Speaking time of Marc Voigt: 1:30pm - 2.00pm (UTC) on Thursday, 17 November 2022
A replay of the webcast is available here
For questions, please email londonhealthcareconf@jefferies.com
Bell Potter Healthcare Conference 2022
Marc Voigt, CEO and Deanne Miller, COO of Immutep will participate in the upcoming virtual conference and will deliver a presentation.
Speaking time of Marc Voigt: 10:00am - 10:30am (AEDT) on Wednesday, 9 November 2022
For question, please email healthcare@bellpotter.com.au
SITC - 37th Annual Meeting & Pre-Conference Programs 2022
The company will participate in the upcoming in-person conference.
Venue: Boston, MA
Ladenburg Thalmann's 2022 Healthcare Conference
Marc Voigt, CEO and Deanne Miller, COO of Immutep will participate in the upcoming conference to present a corporate overview
Cantor Oncology, Hematology & HemeOnc Conference
Marc Voigt, CEO and Deanne Miller, COO will participate in the in-person conference
Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit
Immutep will participate in the 2nd Non-Small Cell Lung Cancer Drug Development Summit
Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:
A Soluble LAG-3 Protein (Eftilagimod Alpha) with an Anti-PD-1 Antibody (Pembrolizumab): Results of a Phase II Study in NSCLC
Speaking time of Frederic Triebel: 12.00 EST, Thursday 22nd September 2022
CLSA 29th Annual CITIC CLSA Flagship Investors' Forum
Marc Voigt, CEO and Deanne Miller, COO of Immutep will participate in the virtual Investor' Forum
E&P’s Inaugural Small Caps Health Care Conference
Marc Voigt, CEO of Immutep will participate in the conference virtually and Deanne Miller, COO will participate in person.
Speaking time of Marc Voigt: 15:50 pm – 16:20 pm AEST on Tuesday, 6 September 2022
2022 World Conference on Lung Cancer
Immutep will attend to the 2022 World Conference on Lung Cancer.
Jefferies Global Healthcare Conference
Marc Voigt, CEO of Immutep will participate in the upcoming in-person conference and will be available for one to one investor meetings in New York City on June 8-10, 2022.
Speaking time of Marc Voigt: 8:30 AM ET on 10 June, 2022
For questions, please email healthcareconference@jefferies.com
A live webcast and replay of the presentation will be made available at https://wsw.com/webcast/jeff240/immp/1851075 and on the Company’s website following the event.
Wilsons Rapid Insights
Marc Voigt, CEO and Deanne Miller, COO will participate in the in-person conference and deliver 45-minute small group briefings with Q&A.
For more information institutional investors should contact Wilsons Corporate Access: Jeanne.Truijens@wilsonsadvisory.com.au or visit: www.wilsonsrapidinsights.com.au
Jefferies Australia MedTech/Biotech Summit
Marc Voigt, CEO of Immutep will participate in the upcoming virtual event and will deliver a presentation.
Speaking time of Marc Voigt: 9.00 am AEST on Friday 27 May, 2022
For more information please email healthcareconference@jefferies.com
ESMO Breast Cancer Congress 2022
Immutep will attend to the ESMO Breast Cancer Congress 2022.
Goldman Sachs 6th Small/Mid-Cap Healthcare Day
The conference will be a virtual format and involve an informal panel discussion followed by Q&A from the audience.
To join the live event, please contact your Goldman Sach’s representative.
Speaking time of Marc Voigt/ CEO: 3:45pm AEST on 29th April
BIO - Europe Spring
Marc Voigt, CEO of Immutep will participate in the upcoming digital event.
European Lung Cancer Congress 2022
Immutep is presenting new data at the European Lung Cancer Congress 2022.
Maxim Growth Conference
CEO Marc Voigt will participate in a fireside chat plus corporate presentation.
Fireside chat time & date: 11:00 am Eastern Daylight Time (EDT) on Monday 28 March 2022.
42nd Annual Cowen Health Care Conference
Marc Voigt, CEO of Immutep will participate in the upcoming digital event.
9:10 am – 9:40 am Eastern Standard Time (EST) on Tuesday 8 March 2022
Webcast: A live webcast of this event, as well as an archived recording, will be available at https://wsw.com/webcast/cowen108/immp/2022543
Management will also be available for 1-on-1 meetings with institutional investors. Investors interested in scheduling a meeting should contact their Cowen representative.
BIO CEO & Investor Conference
Marc Voigt, CEO of Immutep will participate in the upcoming digital event.
11th Annual SVB Leerink Global Healthcare Conference
Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview.
LAG-3 Targeted Drug Development Summit
Marc Voigt, CEO of Immutep will participate in the upcoming digital event and will deliver opening remarks.
Speaking time of Marc Voigt: 9.00 EST/6.00 PST, Wednesday, 26th January 2021
Frederic Triebel, Frédéric Triebel, CSO & CMO of Immutep will deliver a keynote.
Speaking time of Frederic Triebel: 12.00 EST/9.00 PST, Wednesday, 26th January 2021
BIO Partnering at J.P. Morgan Healthcare Conference
Immutep will participate in the BIO One-on-One Partnering at J.P. Morgan Healthcare Conference.
11th Annual LifeSci Partners - Corporate Access Event
Immutep will participate in the virtual Corporate Access Event.
Annual General Meeting 2021
Asia Summit On Global Health
Asia’s Thought-Leadership Platform on Health Innovation and Investment
Deanne Miller, COO and Marc Voigt, CEO of Immutep will attend to the digital event.
Immutep AIPAC Data Global Webast
12th Annual Jefferies London Healthcare Conference
Marc Voigt, CEO of Immutep will attend to the digital event.
Bell Potter Healthcare Conference
Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview.
Presentation Time (AEDT): 10th November, 4:40pm to 5:10pm
SITC - 36th Annual Meeting & Pre-Conference Programs (SITC 2021)
The company will participate in the conference.
Click here for TACTI-002 abstract
Click here for TACTI-003 abstract
Click here for the SITC 2021 - AIPAC Poster
Click here for the SITC 2021 - TACTI-002 Poster
Click here for the SITC 2021 - TACTI-002 Poster with comments
Click here for the SITC 2021 - TACTI-003 Poster
Venue: Walter E. Washington Convention Center in Washington, D.C.
AusBiotech - Australia`s life science conference 2021
Marc Voigt, CEO of Immutep will provide a company presentation.
Session Time: 9.45am – 11.15am (AEDT)
Venue: Online
Goldman Sachs Small/Mid-Cap Healthcare Day
The conference will be a virtual format and involve an informal discussion with Goldman Sachs host (Chris Cooper, Healthcare Analyst Global Investment Research), and Q&A with investors.
To join the live event, please contact your Goldman Sach’s representative.
Speaking time of Marc Voigt/ CEO: 4pm AEST on 7th October
2021 Cantor Virtual Global Healthcare Conference
Immutep will participate in the virtual event format.
ESMO 2021 Congress
Immutep will participate in the virtual ESMO 2021 congress.
Click here for the "INSIGHT - Stratum D" poster which will be presented at the ESMO 2021
ASX Small and Mid-Cap Conference
Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview.
Date : Tuesday, September 14th
Extraordinary General Meeting 2021
Click here for the EGM - Notice of Meeting 2021 Update
Click here for the EGM - Notice of Meeting 2021
Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit
Immutep will participate in the digital Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit.
Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:
A Soluble LAG-3 Protein (Eftilagimod Alpha) with an Anti-PD-1 Antibody (Pembrolizumab): Results of a Phase II Study in NSCLC
Immutep to Present at Ladenburg Thalmann 2021 Healthcare Conference DIGITAL
Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview.
BIO International Convention - Bio Digital 2021
Immutep will participate in the new virtual event format.
ASCO 2021 Annual Meeting
Immutep will participate in this year`s virtual ASCO 2021 Annual Meeting.
Click here for the "TACTI-002_HNSCC" poster which will be presented at the virtual event - ASCO 2021
Click here for the "TACTI-002_NSCLC" poster which will be presented at the virtual event - ASCO 2021
Click here for the "Insight" poster which will be presented at the virtual event - ASCO 2020
BIONNALE 2021
Immutep will participate in this year`s virtual event format.
Cancer Progress by Cello Health - Virtual
Immutep will participate in the virtual event format.
Maxim Group's 2021 Inaugural Emerging Growth Virtual Conference
Marc Voigt, CEO of Immutep has been invited to present at the Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC
Fireside Chat at day 3, 19th | 9:30 AM - 10:00 AM EST
7th Annual Immuno-Oncology 360° Conference
Immutep will participate in the virtual IO 360° conference.
J.P. Morgan 39th Annual Healthcare Conference 2021 DIGITAL
Immutep will participate in the virtual 39th Annual J.P. Morgan Healthcare Conference.
BIO One-on-One Partnering at J.P. Morgan Healthcare Conference
Immutep will participate in the virtual BIO One-on-One Partnering at J.P. Morgan Healthcare Conference.
10th Annual LifeSci Partners Corporate Access Event
Immutep will participate in the virtual 10th Annual Lifesci Partners Corporate Access Event
Immutep AIPAC Data Global Webcast (ASX:IMM; NASDAQ:IMM)
Webcast Details
Immutep will present this AIPAC data in a global webcast for investors, details are as follows:
Date & Time: Friday, 11 December 2020, at 8.30 am Australian Eastern Daylight Time (AEDT) (Thursday, December 10th, at 4:30 p.m. U.S. ET)
Register: http://public.viavid.com/index.php?id=142664
Click here for AIPAC Global Webcast Slides
San Antonio Breast Cancer Symposium 2020 (SABCS)
Immutep will participate in this year`s virtual SABCS 2020 symposium.
SITC - 35th Anniversary Annual Meeting and Pre-Conference Programs (SITC 2020)
Immutep will participate in the virtual SITC 2020 conference.
Click here for the "TACTI-002" poster which was presented at the SITC 2020.
World Immunotherapy Congress 2020
Immutep will participate in the new virtual event format and will present:
A soluble LAG-3 protein (eftilagimod alpha) with an anti-PD-1 antibody (pembrolizumab): results of a phase II study in NSCLC and HNSC
Click here for the video presentation held by Frederic Triebel (CSO & CMO)
BIO-Europe® - 26th Annual International Partnering Conference
Delivered Digitally - European Standard Time
Immutep will participate in the virtual Bio-Europe 2020 conference.
ESMO 2020 Congress - Virtual
Immutep will participate in the virtual ESMO 2020 conference.
H.C. Wainwright 22nd Annual Global Investment Conference
Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview.
Presentation Time (EDT): 15th September, 9:30 to 9:50 AM
BIO International Convention - Bio Digital
Immutep will participate in the new virtual event format.
ASCO 2020 Virtual
Immutep will participate in the new virtual event format and will present:
“Initial results from a Phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab”
&
"Open label, phase I study evaluating feasibility and safety of subcutaneous IMP 321
(a soluble LAG 3 protein, eftilagimod alpha) combined with avelumab in advanced stage
solid tumor entities results from stratum D of the INSIGHT platform trial"
Click here for the "TACTI-002" poster which will be presented at the virtual event - ASCO 2020
Click here for the "Insight" poster which will be presented at the virtual event - ASCO 2020
6TH Annual Digital Immuno-Oncology Innovation Forum
Immutep will participate in the virtual IOIF conference.
ESMO Breast Cancer Congress 2020
Venue: Hub27 Berlin, Messedamm 22, 14055, Berlin, Germany
American Association for Cancer Research (AACR) Annual Meeting 2020
Venue: San Diego Convention Center, San Diego, California, USA
Immutep AIPAC Data Global Webcast (ASX:IMM; NASDAQ:IMMP)
Immutep will present this AIPAC data in a global webcast, details are as follows:
Date & Time: Thursday, March 26th, 8am Australian Eastern Daylight Time / Wednesday, March 25th, 5pm US Eastern Daylight Time
Register: Interested parties can register via a link to the webcast on the Company’s website or via the following link: http://public.viavid.com/index.php?id=138665
Questions: Investors are invited to submit questions in advance via immutep@citadelmagnus.com.
A replay of the webcast will also be available at www.immutep.com from the day after the event.
Click here for AIPAC Global Webcast Slides
Immutep Clinical Results Global Webcast (ASX:IMM; NASDAQ:IMMP)
The Company will present the interim TACTI-002 data and provide a further update on its clinical programs in a global webcast. The details for the webcast are as follows:
Date & Time: Wednesday, February 26, 2020, 8:00 am Australian Eastern Daylight Time / Tuesday, February 25, 2020, 4:00 pm US Eastern Daylight Time
Register: Interested parties can register via a link to the webcast on the Company’s website or via the following link:
https://fnn.webex.com/fnn/onstage/g.php?MTID=e11208a0ff7fcccaca4d5e4b8a14e988f
Questions: Investors are invited to submit questions in advance via immutep@citadelmagnus.com.
A replay of the webcast will also be available at www.immutep.com from the day after the event.
38th Annual J.P. Morgan Health Care Investor Conference
BIO-Europe® - 25th Annual International Partnering Conference
Venue: CCH - Congress Center Hamburg, Am Dammtor / Marseiller Str., 20355 Hamburg, Germany
34th Annual Meeting SITC 2019
The company will have presentations at the conference and representatives will be attending.
Venue: Gaylord National Hotel & Convention Center in National Harbor, 201 Waterfront St, Forest Heights, MD 20745, USA
https://www.nationalharbor.com/gaylord-national/
Click here for the "TACTI-002" poster which will be presented at the SITC 2019
AusBiotech Investment Events 2019
Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update.
Venue: Melbourne Convention & Exhibition Centre, Melbourne VIC 3006, Australia
World Immunotherapy Congress as part of Festival of Biologics 2019
Day 1 – Tuesday, 15th October/ 2.50 p.m.
Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:
A soluble LAG-3 protein (eftilagimod alpha) with an anti-PD-1 antibody (pembrolizumab): a new combination in immuno-oncology
Venue: Basel Congress Centre, Basel, Switzerland
ESMO 2019 Congress
Representatives of the company will be attending the conference.
Venue:
Fira Gran Via, Barcelona
Av. Joan Carles I, 64
08908 L'Hospitalet de Llobregat, Spain
World Advanced Therapies & Regenerative Medicine Congress & Expo 2019
Conference Day 2: Friday 17th May 2019/ 11.25.a.m.
Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:
Combining a soluble LAG-3 protein with an anti-PD-1 antibody in phase I-II trials
Venue: Business Design Centre, London, UK
New York Academy of Sciences, Frontiers in Cancer Immunotherapy
Frédéric Triebel, CSO & CMO of Immutep, will participate in a panel discussion.
Venue: The New York Academy of Sciences, New York, New York, USA
Deutsche Biotechnologietage 2018/German Biotech Days 2018
Venue: BBC (Berlin Congress Center), Alexanderstr. 11, 10178, Berlin, Germany
American Association for Cancer Research (AACR) Annual Meeting 2019
Venue: San Diego Convention Center, San Diego, California, USA
World Immunotherapy Congress USA 2019
Day 2 – Tuesday 5th March/ 3.00 p.m.
Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:
Two ACTive Immunotherapies (TACTI): Results of a Phase I trial with metastatic melanoma patients
Venue: Grand Hyatt, San Diego, USA
37th Annual J.P. Morgan Health Care Investor Conference
Venue: San Francisco, California, USA
4th Annual ICI Europe Summit
conference day 1/ 02.00 p.m.
Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:
Two ACTIve Immunotherapies (TACTI): Results of Phase I Trial With Metastatic Melanoma Patients (TACTI-mel) Treated With a Soluble LAG-3 Receptor (LAG-3lg or Eftilagimod Alpha) as an Antigen Presenting (APC) Activator Combined with Pembrollzumab
Venue: The Sofitel Berlin Kurfuerstendamm, Berlin, Germany
Macquarie Life Sciences Corporate Day - Sydney
Marc Voigt, CEO of Immutep, will present a corporate overview and business update.
Venue: Macquarie Office - Sydney, Australia
33rd Annual Meeting SITC 2018
The company will have presentations at the conference and representatives will be attending.
Venue: Walter E. Washington Convention Center, 801 Mt Vernon Pl NW, Washington, D.C., DC 20001, USA
World Immunotherapy Congress 2018
day 2/ 2:55 p.m.
Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:
Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor
(Eftilagimod Alpha) with Pembrolizumab
Venue: Basel Congress Center, Basel, Switzerland
Australian Biotech Invest & Partnering 2018
Marc Voigt, CEO of Immutep, will present a corporate overview and business update.
Venue: Sofitel Melbourne on Collins, Melbourne VIC 3000, Australia
15th International Congress of the Society for Melanoma Research
Dr. Victoria Atkinson (Principal Investigator TACTI-mel) speaks on the subject:
"Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma."
Venue: Manchester Central Convention Complex, Manchester, United Kingdom
ESMO 2018 Congress
Representatives of the company will be attending the conference.
Venue: Messe Munich, Messegelände, 81823 Munich, Germany, www.messe-muenchen.de
Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference
Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update at 3:30pm ET on Tuesday, October 2, 2018, with one-on-one meetings held throughout the day. The presentation will be webcast live and available for replay via the investor relations section of the company’s website at www.immutep.com.
Listen to the webcast “Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference”
Download "Ladenburg 2018 HC Conference Immutep Presentation"
BioCentury 25th Annual NewsMakers - Biotech Industry Conference
Marc Voigt, CEO of Immutep, will present a corporate overview and business update with one-on-one meetings held throughout the day.
Venue: Millenium Broadway Hotel & Conference Center, NY, USA
Press release: click here
Download "Newsmaker Immutep Corporate Presentation"
Listen to the webcast “Immutep Newsmakers Presentation” from September 7th, 2018
BIONNALE 2018, Berlin, Germany
- the largest networking event for life sciences and healthcare industries in the German capital region -
Venue: Ludwig Erhard Haus, Fasanenstraße 85, Berlin, Germany
Immutep to Participate in the Nasdaq Closing Bell Ceremony at the Nasdaq MarketSite in Times Square, New York on June 1st, 2018
Immutep to Participate in the Nasdaq Closing Bell Ceremony at the Nasdaq MarketSite in Times Square, New York on June 1st, 2018
3rd Annual Advances in Immuno-Oncology Congress, 24 - 25 May 2018, London, UK
Frédéric Triebel speaks on the subject:
“Two ACTIve Immunotherapies in melanoma (TACTI-mel): results of a phase I trial with metastatic melanoma patients treated with a soluble LAG-3 receptor (LAG-3Ig or eftilagimod alpha) as an antigen presenting (APC) activator combined with pembrolizumab.”
13th Annual Advanced Therapy and Regenerative Medicine Congress 2018, 16 – 18 May, London, UK
Frédéric Triebel speaks on the subject:
“LAG-3: the next immune checkpoint after CTLA-4 and PD-1/PDL-1?”
American Association for Cancer Research (AACR) Annual Meeting 2018
Venue: McCormick Place, Chicago, IL, USA
The MicroCap Conference
Company presentation by Jay R. Campbell at 9.00am EDT on Monday, April 9th
Venue: Essex House, New York, NY, USA